Intravitreal Injections

Intravitreal injection (IVI) with administration of various pharmacological agents is a mainstay of treatment in ophthalmology for endopthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, vascular occlusions, and retinal detachment.


The advantage of the IVI technique is the ability to maximize intraocular levels of medications and to avoid the toxicities associated with systemic treatment.

Indication:

1 - Proliferative Diabetic Retinopathy.
2 - Age Related Macular Degeneration (AMD).
3 - Refractory Macular Edema.

Other conditions can benefit from IVI after careful discussion with your doctor.

The label explains that Avastin™ works by blocking a substance known as vascular endothelial growth factor or VEGF. Blocking or inhibiting VEGF helps prevent further growth of the blood vessels.

Types & Popularity:

Since 2000 and 2005, the intravitreal applications of triamcinolone acetonide and bevacizumab/ranibizumab have markedly increased in frequency as therapy of diabetic macular oedema, exudative age-related macular degeneration and other intraocular neovascular or oedematous diseases .


Bevacizumab is commercially known as Avastin™, Rabibizumab is known as Lucentis™.

Complications:

the list of reported complications includes infectious and noninfectious endophthalmitis, secondary ocular hypertension potentially leading to secondary steroid-induced open-angle glaucoma, and iatrogenic lesions to the intraocular structures.